In this regard, it has also been reported that the angiotensin type 1 receptor blocker, candesartan, prevents angiotensin II‐induced downregulation of GLO1 and that this may contribute to its ability to protect against diabetic retinopathy (Miller et al. 2010). This evidence concerns the gene AGT and diabetic retinopathy.